Antibody Affinity maturation is known to improve the antibody-antigen binding kinetics for drug optimization. Despite the popularity of NNK (degenerate primer, N= A/C/G/T, K= G/T) mutagenesis and phage library, inherent limitations exist, such as unequal mutation distribution, WT sequence enrichment, and limited saturation mutation coverage within the Complementarity-Determining Region (CDR).

To address these limitations, Nikebio combined the power of efficient, unbiased mutagenesis by PML (precise mutagenesis library) technology and the high efficiency of the HTP FASEBA (Fast Screening for Expression, Biophysical-properties, and Affinity) affinity screening platform.